Lixte Biotechnology Holdings Inc (XETR:8640) Share Price

Company Profile

Business description
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
Contact
680 East Colorado Boulevard
Suite 180
PasadenaCA91101
USA
T: +1 631 830-7092
https://www.lixte.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
4

Recommended

We were wrong when we thought last quarter would be hard to top.

Dan Romanoff, CPA | 31 July 2025

These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.

Susan Dziubinski | 30 July 2025

We raise our Fair Value estimates but still think that current share prices rely on overly optimistic expectations.

Shaun Ler | 30 July 2025

Index	Last price	Change	% Change
All Ordinaries	8,917.10	81.90	-0.91%
CAC 40	7,546.16	225.81	-2.91%
DAX 40	23,425.97	639.50	-2.66%
Dow JONES (US)	43,588.58	542.40	-1.23%
FTSE 100	9,068.58	64.23	-0.70%
HKSE	24,507.81	265.52	-1.07%
NASDAQ	20,650.13	472.31	-2.24%
Nikkei 225	40,799.60	270.22	-0.66%
NZX 50 Index	12,729.40	94.34	-0.74%
S&P 500	6,238.01	101.38	-1.60%
S&P/ASX 200	8,662.00	80.80	-0.92%
SSE Composite Index	3,559.95	13.26	-0.37%